SCHEMBL3675018

SCHEMBL3675018

c1cc2c(cc1[Zn]c1ccc3c(c1)OCO3)OCO2

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 0.52
ALDH1A1 P00352 3/20 0.47
HSD17B10 Q99714 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
ABCG2 Q9UNQ0 1/20 0.46
MAPK1 P28482 2/20 0.45
TAAR1 Q96RJ0 1/20 0.44
ATM Q13315 1/20 0.44
CMA1 P23946 1/20 0.44
MAPT P10636 4/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
GAA P10253 1/20 0.42
SLC6A4 P31645 1/20 0.42
MEN1 O00255 1/20 0.42
NPC1 O15118 1/20 0.42
POLB P06746 1/20 0.42
RAB9A P51151 1/20 0.42
KMT2A Q03164 1/20 0.42
CYP1A2 P05177 1/20 0.42
HTR3E A5X5Y0 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17188141 0.82 CYP3A4 (0.48) CYP3A4ALDH1A1HSD17B10TDP1ABCG2
SCHEMBL789738 0.73 CYP3A4 (0.54) CYP3A4ALDH1A1HSD17B10TDP1ABCG2
SCHEMBL921252 0.68 CYP3A4 (0.54) CYP3A4ALDH1A1HSD17B10TDP1ABCG2
SCHEMBL1045633 0.68 CYP3A4 (0.54) CYP3A4ALDH1A1HSD17B10TDP1ABCG2
SCHEMBL5682293 0.68 CYP3A4 (0.54) CYP3A4ALDH1A1HSD17B10TDP1ABCG2
SCHEMBL8163694 0.68 CYP3A4 (0.54) CYP3A4ALDH1A1HSD17B10TDP1ABCG2
SCHEMBL8530719 0.68 CYP3A4 (0.54) CYP3A4ALDH1A1HSD17B10TDP1ABCG2
SCHEMBL20959 0.68 CYP3A4 (1.00) CYP3A4ALDH1A1HSD17B10TDP1ABCG2
SCHEMBL22162812 0.68 CA12 (0.58) CYP3A4ALDH1A1HSD17B10TDP1MAPT
SCHEMBL4398810 0.68 CYP3A4 (0.54) CYP3A4ALDH1A1HSD17B10TDP1ABCG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7781599-B2 economical; nontoxic; high yield; industrial scale; Grignard reaction; iron catalyst (FeCl3) and a diamine (ethylenediamine); cross-coupling of alkyl halide and aromatic organometallic; primary or secondary alkyl substituents; phenylcycloheptane from bromocycloheptane and phenyl magnesium bromide JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2010-08-24 US disclosed
US-20070123734-A1 Process for production of aromatic compounds JAPAN SCIENCE AND TECHNOLOGY AGENCY 2007-05-31 US disclosed
EP-1724248-A1 PROCESS FOR PRODUCTION OF AROMATIC COMPOUNDS Japan Science and Technology Agency (JP) 2006-11-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123734-A1 Process for production of aromatic compounds C9, C5, C1S CYP3A4 95/4885ALDH1A1 2363/4885HSD17B10 1266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.